LALL
MCID: LYM138
MIFTS: 43

Lymphoblastic Leukemia, Acute, with Lymphomatous Features (LALL)

Categories: Cancer diseases, Immune diseases

Aliases & Classifications for Lymphoblastic Leukemia, Acute, with Lymphomatous Features

MalaCards integrated aliases for Lymphoblastic Leukemia, Acute, with Lymphomatous Features:

Name: Lymphoblastic Leukemia, Acute, with Lymphomatous Features 58 30 6
Acute Lymphoblastic Leukemia with Lymphomatous Features 74
Leukemia, Acute Lymphoblastic 58
Lymphomatous All 58
Lall 58

Characteristics:

OMIM:

58
Inheritance:
acquired specific neoplasm by autosomal recessive mechanism through somatic cell mutation


HPO:

33
lymphoblastic leukemia, acute, with lymphomatous features:
Inheritance autosomal recessive inheritance


Classifications:



External Ids:

OMIM 58 247640
ICD10 34 C91.0
MedGen 43 C1855472
UMLS 74 C1855472

Summaries for Lymphoblastic Leukemia, Acute, with Lymphomatous Features

MalaCards based summary : Lymphoblastic Leukemia, Acute, with Lymphomatous Features, also known as acute lymphoblastic leukemia with lymphomatous features, is related to leukemia, acute lymphoblastic and leukemia, acute lymphoblastic 3. An important gene associated with Lymphoblastic Leukemia, Acute, with Lymphomatous Features is ABL1 (ABL Proto-Oncogene 1, Non-Receptor Tyrosine Kinase), and among its related pathways/superpathways are Akt Signaling and Cytokine Signaling in Immune system. Affiliated tissues include myeloid, t cells and lymph node, and related phenotypes are lymphoma and t-cell acute lymphoblastic leukemias

Description from OMIM: 247640

Related Diseases for Lymphoblastic Leukemia, Acute, with Lymphomatous Features

Diseases related to Lymphoblastic Leukemia, Acute, with Lymphomatous Features via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 35)
# Related Disease Score Top Affiliating Genes
1 leukemia, acute lymphoblastic 12.9
2 leukemia, acute lymphoblastic 3 12.5
3 leukemia, acute lymphoblastic 2 12.5
4 acute lymphocytic leukemia 11.7
5 lymphocytic leukemia 10.7
6 leukemia 10.7
7 thrombocythemia 3 10.2 INSL6 JAK2
8 lymphoid leukemia 10.2 INSL6 JAK2
9 myeloid and lymphoid neoplasms with eosinophilia and abnormalities of pdgfra, pdgfrb, and fgfr1 10.2 FGFR1 JAK2
10 myelodysplastic myeloproliferative cancer 10.2 ABL1 JAK2
11 jak3-deficient severe combined immunodeficiency 10.1 JAK1 JAK3
12 stuttering 10.1
13 atypical chronic myeloid leukemia 10.1 ABL1 JAK2
14 chronic eosinophilic leukemia 10.1 ABL1 FGFR1
15 primary polycythemia 10.0 ABL1 JAK1 JAK2
16 lactocele 10.0 JAK1 JAK2 JAK3
17 leukemia, acute myeloid 10.0
18 lymphoma 10.0
19 thrombocytopenia-absent radius syndrome 10.0 FGFR1 JAK2
20 t-cell prolymphocytic leukemia 10.0 ABL1 JAK1 JAK3
21 leukemia, chronic myeloid 9.9 ABL1 FGFR1 JAK2
22 severe combined immunodeficiency, x-linked 9.9 IL7R JAK3
23 hematologic cancer 9.9 ABL1 FGFR1 JAK2
24 systemic mastocytosis 9.8 FGFR1 JAK2
25 combined t cell and b cell immunodeficiency 9.8 IL7R JAK3
26 pelger-huet anomaly 9.8
27 acute leukemia 9.8
28 paroxysmal nocturnal hemoglobinuria 9.8
29 hemoglobinuria 9.8
30 childhood leukemia 9.8
31 myeloid leukemia 9.8
32 polycythemia vera 9.8 ABL1 JAK1 JAK2 JAK3
33 myeloproliferative neoplasm 9.7 ABL1 FGFR1 JAK2 JAK3
34 bone marrow cancer 9.7 ABL1 FGFR1 JAK2 JAK3
35 interleukin-7 receptor alpha deficiency 9.7 CRLF2 IL7R JAK3

Graphical network of the top 20 diseases related to Lymphoblastic Leukemia, Acute, with Lymphomatous Features:



Diseases related to Lymphoblastic Leukemia, Acute, with Lymphomatous Features

Symptoms & Phenotypes for Lymphoblastic Leukemia, Acute, with Lymphomatous Features

Human phenotypes related to Lymphoblastic Leukemia, Acute, with Lymphomatous Features:

33
# Description HPO Frequency HPO Source Accession
1 lymphoma 33 HP:0002665
2 t-cell acute lymphoblastic leukemias 33 HP:0006727

Symptoms via clinical synopsis from OMIM:

58
Heme:
acute lymphoblastic leukemia (all)
lymphomatous all (lall)
t-cell all

Lab:
chromosome loss of bands 9p22-p21 by deletion, unbalanced translocation, or loss of entire chromosome
loss of methylthioadenosine phosphorylase in malignant cells during relapse

Misc:
bulky disease of lymph nodes, spleen, and mediastinum

Clinical features from OMIM:

247640

GenomeRNAi Phenotypes related to Lymphoblastic Leukemia, Acute, with Lymphomatous Features according to GeneCards Suite gene sharing:

27 (show all 37)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00221-A-1 10 ABL1 FGFR1
2 Decreased viability GR00221-A-2 10 ABL1 FGFR1 JAK1 JAK2
3 Decreased viability GR00221-A-3 10 ABL1
4 Decreased viability GR00342-S-1 10 ABL1
5 Decreased viability GR00342-S-2 10 ABL1
6 Decreased viability GR00342-S-3 10 ABL1
7 Decreased viability GR00402-S-2 10 ABL1 FGFR1 JAK1 JAK2
8 Increased shRNA abundance (Z-score > 2) GR00366-A-100 9.88 ABL1 FGFR1
9 Increased shRNA abundance (Z-score > 2) GR00366-A-105 9.88 ABL1 JAK3
10 Increased shRNA abundance (Z-score > 2) GR00366-A-11 9.88 JAK3
11 Increased shRNA abundance (Z-score > 2) GR00366-A-123 9.88 ABL1
12 Increased shRNA abundance (Z-score > 2) GR00366-A-125 9.88 FGFR1
13 Increased shRNA abundance (Z-score > 2) GR00366-A-126 9.88 FGFR1
14 Increased shRNA abundance (Z-score > 2) GR00366-A-143 9.88 IL7R
15 Increased shRNA abundance (Z-score > 2) GR00366-A-149 9.88 JAK3
16 Increased shRNA abundance (Z-score > 2) GR00366-A-151 9.88 ABL1
17 Increased shRNA abundance (Z-score > 2) GR00366-A-156 9.88 IL7R
18 Increased shRNA abundance (Z-score > 2) GR00366-A-157 9.88 ABL1
19 Increased shRNA abundance (Z-score > 2) GR00366-A-169 9.88 FGFR1
20 Increased shRNA abundance (Z-score > 2) GR00366-A-183 9.88 FGFR1
21 Increased shRNA abundance (Z-score > 2) GR00366-A-189 9.88 IL7R
22 Increased shRNA abundance (Z-score > 2) GR00366-A-195 9.88 JAK3
23 Increased shRNA abundance (Z-score > 2) GR00366-A-197 9.88 IL7R
24 Increased shRNA abundance (Z-score > 2) GR00366-A-2 9.88 IL7R
25 Increased shRNA abundance (Z-score > 2) GR00366-A-3 9.88 ABL1
26 Increased shRNA abundance (Z-score > 2) GR00366-A-30 9.88 ABL1
27 Increased shRNA abundance (Z-score > 2) GR00366-A-43 9.88 ABL1 FGFR1 IL7R JAK3
28 Increased shRNA abundance (Z-score > 2) GR00366-A-47 9.88 ABL1 FGFR1
29 Increased shRNA abundance (Z-score > 2) GR00366-A-50 9.88 FGFR1
30 Increased shRNA abundance (Z-score > 2) GR00366-A-6 9.88 JAK3
31 Increased shRNA abundance (Z-score > 2) GR00366-A-65 9.88 ABL1
32 Increased shRNA abundance (Z-score > 2) GR00366-A-73 9.88 FGFR1
33 Increased shRNA abundance (Z-score > 2) GR00366-A-83 9.88 ABL1 FGFR1
34 Increased shRNA abundance (Z-score > 2) GR00366-A-85 9.88 ABL1 JAK3
35 Increased shRNA abundance (Z-score > 2) GR00366-A-96 9.88 JAK3
36 Decreased human cytomegalovirus (HCMV) strain AD169 replication GR00248-A 9.56 ABL1 FGFR1 JAK1 JAK3
37 Decreased viability in HMC1.1 cells GR00105-A-0 8.96 JAK1 JAK3

MGI Mouse Phenotypes related to Lymphoblastic Leukemia, Acute, with Lymphomatous Features:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 9.8 ABL1 CRLF2 FGFR1 IL7R INSL6 JAK2
2 endocrine/exocrine gland MP:0005379 9.76 ABL1 CRLF2 FGFR1 IL7R INSL6 JAK1
3 hematopoietic system MP:0005397 9.56 ABL1 CRLF2 FGFR1 IL7R JAK1 JAK2
4 immune system MP:0005387 9.17 ABL1 CRLF2 FGFR1 IL7R JAK1 JAK2

Drugs & Therapeutics for Lymphoblastic Leukemia, Acute, with Lymphomatous Features

Search Clinical Trials , NIH Clinical Center for Lymphoblastic Leukemia, Acute, with Lymphomatous Features

Genetic Tests for Lymphoblastic Leukemia, Acute, with Lymphomatous Features

Genetic tests related to Lymphoblastic Leukemia, Acute, with Lymphomatous Features:

# Genetic test Affiliating Genes
1 Lymphoblastic Leukemia, Acute, with Lymphomatous Features 30

Anatomical Context for Lymphoblastic Leukemia, Acute, with Lymphomatous Features

MalaCards organs/tissues related to Lymphoblastic Leukemia, Acute, with Lymphomatous Features:

42
Myeloid, T Cells, Lymph Node, Spleen, Bone, Bone Marrow, B Cells

Publications for Lymphoblastic Leukemia, Acute, with Lymphomatous Features

Articles related to Lymphoblastic Leukemia, Acute, with Lymphomatous Features:

# Title Authors Year
1
Re-evaluation of endogenous development of Eimeria bareillyi Gill, Chhabra and Lall, 1963 in water buffalo (Bubalus bubalis). ( 29692286 )
2018
2
Authentication of Angelica anomala Avé-Lall cultivars through DNA barcodes. ( 22397381 )
2012
3
Molecular analysis of the CALM/AF10 fusion: identical rearrangements in acute myeloid leukemia, acute lymphoblastic leukemia and malignant lymphoma patients. ( 10637482 )
2000
4
Expression of MDR1 gene in acute leukemia cells: association with CD7+ acute myeloblastic leukemia/acute lymphoblastic leukemia. ( 7694687 )
1993
5
The constitution of anomalin, a new coumarin isolated from the root of Angelica anomala Lall. (umbelliferae). ( 5920524 )
1966

Variations for Lymphoblastic Leukemia, Acute, with Lymphomatous Features

ClinVar genetic disease variations for Lymphoblastic Leukemia, Acute, with Lymphomatous Features:

6 (show all 33)
# Gene Variation Type Significance SNP ID Assembly Location
1 ABL1 NM_007313.2(ABL1): c.1001C> T (p.Thr334Ile) single nucleotide variant Pathogenic/Likely pathogenic rs121913459 GRCh37 Chromosome 9, 133748283: 133748283
2 ABL1 NM_007313.2(ABL1): c.1001C> T (p.Thr334Ile) single nucleotide variant Pathogenic/Likely pathogenic rs121913459 GRCh38 Chromosome 9, 130872896: 130872896
3 ABL1 NM_007313.2(ABL1): c.814T> C (p.Tyr272His) single nucleotide variant Pathogenic/Likely pathogenic rs121913461 GRCh37 Chromosome 9, 133738357: 133738357
4 ABL1 NM_007313.2(ABL1): c.814T> C (p.Tyr272His) single nucleotide variant Pathogenic/Likely pathogenic rs121913461 GRCh38 Chromosome 9, 130862970: 130862970
5 JAK3 NM_000215.3(JAK3): c.2164G> A (p.Val722Ile) single nucleotide variant Conflicting interpretations of pathogenicity rs3213409 GRCh37 Chromosome 19, 17945696: 17945696
6 JAK3 NM_000215.3(JAK3): c.2164G> A (p.Val722Ile) single nucleotide variant Conflicting interpretations of pathogenicity rs3213409 GRCh38 Chromosome 19, 17834887: 17834887
7 JAK3 NM_000215.3(JAK3): c.394C> A (p.Pro132Thr) single nucleotide variant Conflicting interpretations of pathogenicity rs3212723 GRCh37 Chromosome 19, 17954215: 17954215
8 JAK3 NM_000215.3(JAK3): c.394C> A (p.Pro132Thr) single nucleotide variant Conflicting interpretations of pathogenicity rs3212723 GRCh38 Chromosome 19, 17843406: 17843406
9 FGFR1 NM_023110.2(FGFR1): c.1966A> G (p.Lys656Glu) single nucleotide variant Pathogenic/Likely pathogenic rs869320694 GRCh37 Chromosome 8, 38272308: 38272308
10 FGFR1 NM_023110.2(FGFR1): c.1966A> G (p.Lys656Glu) single nucleotide variant Pathogenic/Likely pathogenic rs869320694 GRCh38 Chromosome 8, 38414790: 38414790
11 JAK1 NM_002227.3(JAK1): c.1901C> A (p.Ala634Asp) single nucleotide variant Likely pathogenic rs869312953 GRCh37 Chromosome 1, 65312418: 65312418
12 JAK1 NM_002227.3(JAK1): c.1901C> A (p.Ala634Asp) single nucleotide variant Likely pathogenic rs869312953 GRCh38 Chromosome 1, 64846735: 64846735
13 INSL6; JAK2 NM_004972.3(JAK2): c.2047A> G (p.Arg683Gly) single nucleotide variant Pathogenic/Likely pathogenic rs1057519721 GRCh37 Chromosome 9, 5078360: 5078360
14 INSL6; JAK2 NM_004972.3(JAK2): c.2047A> G (p.Arg683Gly) single nucleotide variant Pathogenic/Likely pathogenic rs1057519721 GRCh38 Chromosome 9, 5078360: 5078360
15 INSL6; JAK2 NM_004972.3(JAK2): c.2048G> C (p.Arg683Thr) single nucleotide variant Pathogenic rs1057519722 GRCh37 Chromosome 9, 5078361: 5078361
16 INSL6; JAK2 NM_004972.3(JAK2): c.2048G> C (p.Arg683Thr) single nucleotide variant Pathogenic rs1057519722 GRCh38 Chromosome 9, 5078361: 5078361
17 INSL6; JAK2 NM_004972.3(JAK2): c.2049A> C (p.Arg683Ser) single nucleotide variant Pathogenic rs1057519723 GRCh37 Chromosome 9, 5078362: 5078362
18 INSL6; JAK2 NM_004972.3(JAK2): c.2049A> C (p.Arg683Ser) single nucleotide variant Pathogenic rs1057519723 GRCh38 Chromosome 9, 5078362: 5078362
19 INSL6; JAK2 NM_004972.3(JAK2): c.2049A> T (p.Arg683Ser) single nucleotide variant Pathogenic rs1057519723 GRCh37 Chromosome 9, 5078362: 5078362
20 INSL6; JAK2 NM_004972.3(JAK2): c.2049A> T (p.Arg683Ser) single nucleotide variant Pathogenic rs1057519723 GRCh38 Chromosome 9, 5078362: 5078362
21 CRLF2 NM_022148.3(CRLF2): c.695T> G (p.Phe232Cys) single nucleotide variant Pathogenic rs1057519743 GRCh37 Chromosome X, 1314966: 1314966
22 CRLF2 NM_022148.3(CRLF2): c.695T> G (p.Phe232Cys) single nucleotide variant Pathogenic rs1057519743 GRCh38 Chromosome X, 1196852: 1196852
23 CRLF2 NM_022148.3(CRLF2): c.695T> G (p.Phe232Cys) single nucleotide variant Pathogenic rs1057519743 GRCh38 Chromosome Y, 1196852: 1196852
24 JAK1 NM_002227.3(JAK1): c.1972G> T (p.Val658Phe) single nucleotide variant Likely pathogenic rs1057519753 GRCh37 Chromosome 1, 65312347: 65312347
25 JAK1 NM_002227.3(JAK1): c.1972G> T (p.Val658Phe) single nucleotide variant Likely pathogenic rs1057519753 GRCh38 Chromosome 1, 64846664: 64846664
26 IL7R NM_002185.4(IL7R): c.553A> T (p.Ser185Cys) single nucleotide variant Likely pathogenic rs1057519759 GRCh37 Chromosome 5, 35873597: 35873597
27 IL7R NM_002185.4(IL7R): c.553A> T (p.Ser185Cys) single nucleotide variant Likely pathogenic rs1057519759 GRCh38 Chromosome 5, 35873495: 35873495
28 JAK1 NM_002227.3(JAK1): c.1937C> T (p.Ser646Phe) single nucleotide variant Likely pathogenic rs151047872 GRCh37 Chromosome 1, 65312382: 65312382
29 JAK1 NM_002227.3(JAK1): c.1937C> T (p.Ser646Phe) single nucleotide variant Likely pathogenic rs151047872 GRCh38 Chromosome 1, 64846699: 64846699
30 NT5C2 NM_012229.4(NT5C2): c.1075A> C (p.Lys359Gln) single nucleotide variant not provided rs1057519867 GRCh37 Chromosome 10, 104852980: 104852980
31 NT5C2 NM_012229.4(NT5C2): c.1075A> C (p.Lys359Gln) single nucleotide variant not provided rs1057519867 GRCh38 Chromosome 10, 103093223: 103093223
32 FGFR1 NM_023110.2(FGFR1): c.1968G> C (p.Lys656Asn) single nucleotide variant Likely pathogenic rs1057519897 GRCh37 Chromosome 8, 38272306: 38272306
33 FGFR1 NM_023110.2(FGFR1): c.1968G> C (p.Lys656Asn) single nucleotide variant Likely pathogenic rs1057519897 GRCh38 Chromosome 8, 38414788: 38414788

Expression for Lymphoblastic Leukemia, Acute, with Lymphomatous Features

Search GEO for disease gene expression data for Lymphoblastic Leukemia, Acute, with Lymphomatous Features.

Pathways for Lymphoblastic Leukemia, Acute, with Lymphomatous Features

Pathways related to Lymphoblastic Leukemia, Acute, with Lymphomatous Features according to GeneCards Suite gene sharing:

(show all 41)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.21 FGFR1 IL7R JAK1 JAK2 JAK3
2
Show member pathways
13.15 FGFR1 IL7R JAK1 JAK2 JAK3
3
Show member pathways
12.76 FGFR1 IL7R JAK1 JAK2 JAK3
4
Show member pathways
12.68 FGFR1 JAK1 JAK2 JAK3
5
Show member pathways
12.58 IL7R JAK1 JAK2 JAK3
6 12.52 ABL1 FGFR1 IL7R JAK1 JAK2 JAK3
7
Show member pathways
12.49 FGFR1 JAK1 JAK2 JAK3
8
Show member pathways
12.23 JAK1 JAK2 JAK3
9
Show member pathways
12.22 JAK1 JAK2 JAK3
10
Show member pathways
12.16 JAK1 JAK2 JAK3
11
Show member pathways
12.09 FGFR1 JAK1 JAK2 JAK3
12
Show member pathways
12.08 JAK1 JAK2 JAK3
13
Show member pathways
12.04 FGFR1 IL7R JAK1
14
Show member pathways
12.04 JAK1 JAK2 JAK3
15 12.01 ABL1 JAK1 JAK2
16
Show member pathways
11.97 JAK1 JAK2 JAK3
17 11.96 FGFR1 IL7R JAK1
18 11.95 ABL1 FGFR1 JAK2
19
Show member pathways
11.89 JAK1 JAK2 JAK3
20
Show member pathways
11.87 JAK1 JAK2 JAK3
21
Show member pathways
11.86 FGFR1 IL7R JAK1 JAK2
22 11.85 FGFR1 JAK1 JAK2 JAK3
23 11.79 JAK1 JAK2 JAK3
24
Show member pathways
11.77 JAK1 JAK2 JAK3
25
Show member pathways
11.68 JAK1 JAK2 JAK3
26
Show member pathways
11.47 ABL1 CRLF2 IL7R JAK1 JAK2 JAK3
27 11.45 JAK1 JAK2 JAK3
28 11.33 JAK1 JAK2
29
Show member pathways
11.3 JAK1 JAK2
30
Show member pathways
11.3 JAK1 JAK3
31
Show member pathways
11.3 IL7R JAK1 JAK3
32 11.3 ABL1 IL7R JAK1 JAK2 JAK3
33
Show member pathways
11.26 JAK1 JAK2
34 11.23 IL7R JAK3
35 11.23 CRLF2 IL7R JAK1 JAK2
36 11.22 JAK1 JAK2
37 11.21 JAK1 JAK2 JAK3
38 11.19 FGFR1 JAK1 JAK2 JAK3
39 11.12 CRLF2 JAK1 JAK2 JAK3
40 10.99 IL7R JAK1 JAK3
41 10.9 JAK1 JAK2

GO Terms for Lymphoblastic Leukemia, Acute, with Lymphomatous Features

Cellular components related to Lymphoblastic Leukemia, Acute, with Lymphomatous Features according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 endomembrane system GO:0012505 8.8 JAK1 JAK2 JAK3

Biological processes related to Lymphoblastic Leukemia, Acute, with Lymphomatous Features according to GeneCards Suite gene sharing:

(show all 27)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 9.91 CRLF2 FGFR1 IL7R JAK2
2 protein phosphorylation GO:0006468 9.8 ABL1 FGFR1 JAK1 JAK2 JAK3
3 protein autophosphorylation GO:0046777 9.77 ABL1 FGFR1 JAK2
4 MAPK cascade GO:0000165 9.67 FGFR1 JAK1 JAK2 JAK3
5 phosphorylation GO:0016310 9.65 ABL1 FGFR1 JAK1 JAK2 JAK3
6 erythrocyte differentiation GO:0030218 9.63 JAK2 JAK3
7 interleukin-12-mediated signaling pathway GO:0035722 9.63 JAK1 JAK2
8 B cell proliferation GO:0042100 9.62 ABL1 IL7R
9 platelet-derived growth factor receptor signaling pathway GO:0048008 9.62 ABL1 JAK2
10 response to antibiotic GO:0046677 9.61 JAK1 JAK2
11 interleukin-6-mediated signaling pathway GO:0070102 9.59 JAK1 JAK2
12 negative regulation of cell-cell adhesion GO:0022408 9.58 ABL1 JAK2
13 interleukin-15-mediated signaling pathway GO:0035723 9.58 JAK1 JAK3
14 JAK-STAT cascade involved in growth hormone signaling pathway GO:0060397 9.57 JAK2 JAK3
15 regulation of interferon-gamma-mediated signaling pathway GO:0060334 9.56 JAK1 JAK2
16 interleukin-27-mediated signaling pathway GO:0070106 9.55 JAK1 JAK2
17 cytokine-mediated signaling pathway GO:0019221 9.55 CRLF2 IL7R JAK1 JAK2 JAK3
18 interleukin-2-mediated signaling pathway GO:0038110 9.54 JAK1 JAK3
19 interleukin-35-mediated signaling pathway GO:0070757 9.52 JAK1 JAK2
20 regulation of JAK-STAT cascade GO:0046425 9.51 JAK2 JAK3
21 interleukin-9-mediated signaling pathway GO:0038113 9.49 JAK1 JAK3
22 tyrosine phosphorylation of STAT protein GO:0007260 9.48 JAK2 JAK3
23 enzyme linked receptor protein signaling pathway GO:0007167 9.46 JAK2 JAK3
24 interleukin-21-mediated signaling pathway GO:0038114 9.43 JAK1 JAK3
25 peptidyl-tyrosine phosphorylation GO:0018108 9.35 ABL1 FGFR1 JAK1 JAK2 JAK3
26 positive regulation of STAT cascade GO:1904894 9.32 CRLF2 IL7R
27 interleukin-7-mediated signaling pathway GO:0038111 8.92 CRLF2 IL7R JAK1 JAK3

Molecular functions related to Lymphoblastic Leukemia, Acute, with Lymphomatous Features according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 ATP binding GO:0005524 9.85 ABL1 FGFR1 JAK1 JAK2 JAK3
2 kinase activity GO:0016301 9.72 ABL1 FGFR1 JAK1 JAK2 JAK3
3 protein kinase activity GO:0004672 9.65 ABL1 FGFR1 JAK1 JAK2 JAK3
4 nucleotide binding GO:0000166 9.55 FGFR1 JAK1 JAK2 JAK3 NT5C2
5 cytokine receptor activity GO:0004896 9.43 CRLF2 IL7R
6 SH2 domain binding GO:0042169 9.4 ABL1 JAK2
7 growth hormone receptor binding GO:0005131 9.37 JAK1 JAK2
8 protein tyrosine kinase activity GO:0004713 9.35 ABL1 FGFR1 JAK1 JAK2 JAK3
9 non-membrane spanning protein tyrosine kinase activity GO:0004715 8.92 ABL1 JAK1 JAK2 JAK3

Sources for Lymphoblastic Leukemia, Acute, with Lymphomatous Features

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....